RT Journal Article
SR Electronic
T1 <sup>123</sup>I-MIBG Imaging: Patient Preparation and Technologist’s Role
JF Journal of Nuclear Medicine Technology
JO J. Nucl. Med. Technol.
FD Society of Nuclear Medicine
SP 82
OP 86
DO 10.2967/jnmt.115.158394
VO 43
IS 2
A1 S. Seth Van Vickle
A1 Randall C. Thompson
YR 2015
UL http://tech.snmjournals.org/content/43/2/82.abstract
AB The radiopharmaceutical 123I-metaiodobenzylguanidine (MIBG) was approved by the Food and Drug Administration in March 2013 for the assessment of myocardial sympathetic innervation in the evaluation of patients with heart failure and an ejection fraction of no more than 35%. Almost any well-equipped nuclear medicine or nuclear cardiology laboratory can perform this test, although there is a need for special attention to patient preparation, dose calibration, and proper timing of the image acquisition. This article reviews the role of the nuclear medicine technologist and some practical aspects of cardiac sympathetic 123I-MIBG imaging of which the laboratory team needs to be mindful.